Cell & Gene Therapy
Uncover the transformative potential of cell and gene therapies. Delve into groundbreaking research, clinical advancements, and regulatory developments in this cutting-edge field. Stay informed about the latest breakthroughs and their impact on patient care and disease treatment.
Krystal’s Vyjuvek Gene Therapy Gains FDA Approval, Spurs Sales Projections
Krystal Biotech’s CEO, Krish Krishnan, was quick to highlight in the company’s inaugural conference call to present its quarterly results ...
Vertex Gears Up for exa-cel Launch, Acknowledges Vast Opportunity with Cautious Outlook
After a prolonged journey in development, the first CRISPR-based gene editing therapy has recently received approval from an FDA advisory ...
Catalent Braces for Potential Revenue Setback Following Sarepta’s Gene Therapy Trial Disappointment
Catalent, having overcome the challenges posed by the pandemic, now faces another potential setback in the form of what analysts ...
Nkartaās breakthrough cell therapy for lupus gets FDA approval after showing promise in cancer treatment
In a groundbreaking development, Nkarta is pushing the boundaries of cell therapy beyond the realm of cancer. The FDA has ...
Takedaās Alofisel fails to meet primary endpoint in phase 3 trial for Crohnās disease complication
Takeda, following its decision to remove an early-stage Crohn’s disease candidate from its pipeline earlier this year, is now contending ...
Kyowa Kirin to buy Orchard Therapeutics for $387M, expanding gene therapy portfolio
Kyowa Kirin has responded to the need to strengthen its late-phase pipeline by finalizing a deal to acquire Orchard Therapeutics ...
Bluebird partners with Lonza to increase production of its gene therapies for rare diseases
As bluebird bio takes flight with its high-priced gene therapies, the company is enhancing its manufacturing capabilities through a strategic ...
AbbVie drops Caribouās CRISPR-edited CAR-T therapies after failed trials
AbbVie has chosen to end its partnership with Caribou Biosciences, signaling a significant shift in its strategic focus. This decision ...
Novo Nordisk Foundation Cellerator to boost cell therapy development and production in Denmark
The Novo Nordisk Foundation is embarking on a mission to establish a pivotal “hub” within the cell therapy ecosystem by ...
Mesoblast hopes to win FDA approval for remestemcel-L after meeting with regulators
Mesoblast, a biotech company based in Melbourne, Australia, is making determined strides toward securing FDA approval for its off-the-shelf therapy, ...
Taysha halts gene therapy for rare nerve disease after FDA and Astellas feedback
Astellas has declined the opportunity to exercise an option for an asset from Taysha Gene Therapies. Taysha, facing study design ...
Iovanceās cell therapy for skin cancer faces three-year delay due to FDA issues
The FDA has introduced a new twist in the ongoing Iovance Biotherapeutics saga, causing further delays in the approval process ...
BioMarin R&D chief reveals two new pipeline candidates and strategy to sustain innovation
BioMarin, the California-based biotech giant, is embarking on a mission to create its most robust pipeline in history, with a ...
Calidi Biotherapeutics goes public through SPAC deal to advance off-the-shelf cancer treatments
Calidi Biotherapeutics, a San Diego-based biotech, has chosen the special purpose acquisition company (SPAC) path to enter the public market, ...
Ferring launches bladder cancer gene therapy Adstiladrin in US through early experience program
Ferring Pharmaceuticals achieved a significant milestone by administering its groundbreaking gene therapy, Adstiladrin, to its first commercial patient. This innovative ...
2seventy Bio slashes 176 jobs and looks for new CEO after cell therapy setback
2seventy bio, the spinoff from bluebird bio, is undergoing significant changes under the leadership of CEO Nick Leschly. The company ...
FDA approves Aphexda for stem cell mobilization in multiple myeloma
After a decade of limited progress, the FDA has granted approval for the use of BioLineRx’s motixafortide, also known as ...
Novartis drops Gyroscopeās gene therapy for eye disease after disappointing trial results
Novartis is in the process of divesting its eye disease unit, a move that includes discontinuing a geographic atrophy (GA) ...
Otsuka and Shape Therapeutics join forces to create gene therapies for eye diseases using AI-powered platform
Just a week after Otsuka Pharmaceutical ventured into the psychedelics sector, the Japanese pharmaceutical giant has struck a collaboration deal ...
BlueWhale Bio Emerges With $18m To Tackle Cell Therapy Manufacturing Challenges
BlueWhale Bio, a spinout from the University of Pennsylvania, has emerged with a bold mission to tackle bottlenecks in the ...
Kriya Acquires Gene Therapy Biotech To Enter NASH Market With Novel Approach
Kriya Therapeutics, a prominent player in the biotech industry, has continued its acquisition spree, this time securing Tramontane Therapeutics to ...
Mesoblast CEO Slashes Salary by 30% to Fund Cell Therapy Trial
In a bold move reflecting commitment to the company’s mission, Mesoblast’s CEO has chosen to lead by example by implementing ...
Bristol Myers Squibb’s Bold Robotic Alliance with Cellares for Advanced CAR-T Production
In the realm of cutting-edge cell therapy, where innovation is the heartbeat and the promise of transformative treatments is the ...
Bayer Advances Parkinsonās Cell Therapy to Phase 2 Trial
A new horizon gleams for Bayer’s quest to conquer Parkinson’s disease through advanced cell therapy. In a significant revelation, the ...
Ferring Strikes $500M Agreement with Royalty Pharma for Innovative Bladder Cancer Gene Therapy
Royalty Pharma has carved a distinctive niche in the pharmaceutical landscape, specializing in identifying innovative products both pre- and post-approval, ...
Fulcrum’s Sickle Cell Disease Program Resumes as FDA Lifts 6-Month Hold
Fulcrum Therapeutics’ ambitions in the realm of sickle cell disease (SCD) have been revitalised after a six-month hiatus. The FDA ...
Nobel Prize Winnerās Biotech Company Escapes the Graveyard with SPAC
Reviving a Silent Spell: Celixir, a UK-based cell therapy biotech, emerges from the shadows with a transformative move. Following a ...
Gene Therapy Vector Lawsuit: Henrietta Lacks’ Estate Targets Ultragenyx Over Exploitation
Just under a month after reaching a settlement with Thermo Fisher over the utilization of Henrietta Lacks’ cells, her family ...
Despite CSL’s hemophilia B gene therapy, NICE is not persuaded
The UK’s National Institute for Health and Care Excellence (NICE) has expressed hesitation in recommending approval for CSL Behring and ...
Sensorion Seeks Approval for Clinical Trial of OTOF-GT Gene Therapy Candidate in the UK
Source – Sensorion On July 10, Sensorion filed its first regulatory application to start human testing of OTOF-GT, a gene ...
